These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446 [TBL] [Abstract][Full Text] [Related]
4. Ofatumumab (Arzerra) for CLL. Med Lett Drugs Ther; 2010 Jun; 52(1341):51-2. PubMed ID: 20585286 [No Abstract] [Full Text] [Related]
5. Ofatumumab approved for advanced CLL. Traynor K Am J Health Syst Pharm; 2009 Dec; 66(23):2062. PubMed ID: 19923303 [No Abstract] [Full Text] [Related]
6. Ofatumumab for the treatment of chronic lymphocytic leukemia. Grosicki S Expert Rev Hematol; 2015 Jun; 8(3):265-72. PubMed ID: 25882470 [TBL] [Abstract][Full Text] [Related]
7. Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Ogura M; Hatake K; Tobinai K; Uchida T; Suzuki T; Terui Y; Yokoyama M; Maruyama D; Mori M; Jewell RC; Katsura K; Hotta T Jpn J Clin Oncol; 2013 May; 43(5):466-75. PubMed ID: 23456745 [TBL] [Abstract][Full Text] [Related]
8. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. Nightingale G Ann Pharmacother; 2011 Oct; 45(10):1248-55. PubMed ID: 21896924 [TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. Struemper H; Sale M; Patel BR; Østergaard M; Österborg A; Wierda WG; Hagenbeek A; Coiffier B; Jewell RC J Clin Pharmacol; 2014 Jul; 54(7):818-27. PubMed ID: 24443277 [TBL] [Abstract][Full Text] [Related]
10. [Pharmacological profile of human-type anti-CD20 antibody ofatumumab (Arzerra(®)) and its clinical study results]. Yoshizaki H; Tomonari A Nihon Yakurigaku Zasshi; 2014 Jan; 143(1):40-3. PubMed ID: 24420136 [No Abstract] [Full Text] [Related]